Cargando…

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clinical factors that could be used to predict effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warren, R.B., Marsden, A., Tomenson, B., Mason, K.J., Soliman, M.M., Burden, A.D., Reynolds, N.J., Stocken, D., Emsley, R., Griffiths, C.E.M., Smith, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519065/ https://www.ncbi.nlm.nih.gov/pubmed/30155885 http://dx.doi.org/10.1111/bjd.16776

Ejemplares similares

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
por: Mason, K.J., et al.
Publicado: (2019)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Z.Z.N., et al.
Publicado: (2018)

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
por: Rungapiromnan, W., et al.
Publicado: (2017)

Psoriasis, COVID‐19 and shielding
por: Becher, G., et al.
Publicado: (2021)

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
por: Warren, RB, et al.
Publicado: (2009)

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
por: Wilkinson, Nina, et al.
Publicado: (2019)

Treatment of severe psoriasis with infliximab
por: Leman, JA, et al.
Publicado: (2008)

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008)

Risk of COVID‐19 infection in adult patients with atopic eczema and psoriasis: a single‐centre cross‐sectional study
por: Yiu, Z.Z.N., et al.
Publicado: (2021)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022)

Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)
por: Cro, S., et al.
Publicado: (2021)

Clinical Disease Measures in Generalized Pustular Psoriasis
por: Burden, A. David, et al.
Publicado: (2022)

A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
por: Cro, Suzie, et al.
Publicado: (2020)

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
por: Thorneloe, R.J., et al.
Publicado: (2016)

A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
por: Cornelius, Victoria, et al.
Publicado: (2018)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength
por: Thorneloe, Rachael J., et al.
Publicado: (2018)

The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership
por: Majeed‐Ariss, R., et al.
Publicado: (2019)

The global state of psoriasis disease epidemiology: a workshop report
por: Griffiths, C.E.M., et al.
Publicado: (2017)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study
por: Springate, D.A., et al.
Publicado: (2016)

Genetic susceptibility to psoriasis: an emerging picture
por: Smith, Rhodri Ll, et al.
Publicado: (2009)

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
por: Yiu, Zenas Z. N., et al.
Publicado: (2020)

What are the barriers to physical activity in patients with chronic plaque psoriasis?
por: Auker, L., et al.
Publicado: (2020)

A novel mutation in IL36RN underpins childhood pustular dermatosis
por: Ellingford, J.M., et al.
Publicado: (2015)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)

‘Mind the gap’: what patients and clinicians believe is ‘unknown’ about psoriasis
por: Majeed‐Ariss, R., et al.
Publicado: (2020)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Iskandar, Ireny Y.K., et al.
Publicado: (2018)

A rapid access clinic for psoriasis: first experiences
por: Reid, Claire, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ekboj3un81ssfmaghjsu471u7